GB0307472D0 - Medical treatment - Google Patents

Medical treatment

Info

Publication number
GB0307472D0
GB0307472D0 GBGB0307472.1A GB0307472A GB0307472D0 GB 0307472 D0 GB0307472 D0 GB 0307472D0 GB 0307472 A GB0307472 A GB 0307472A GB 0307472 D0 GB0307472 D0 GB 0307472D0
Authority
GB
United Kingdom
Prior art keywords
medical treatment
medical
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0307472.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Ltd
Original Assignee
Lorantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lorantis Ltd filed Critical Lorantis Ltd
Priority to GBGB0307472.1A priority Critical patent/GB0307472D0/en
Publication of GB0307472D0 publication Critical patent/GB0307472D0/en
Priority to PCT/GB2004/001379 priority patent/WO2004087195A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
GBGB0307472.1A 2003-04-01 2003-04-01 Medical treatment Ceased GB0307472D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0307472.1A GB0307472D0 (en) 2003-04-01 2003-04-01 Medical treatment
PCT/GB2004/001379 WO2004087195A2 (en) 2003-04-01 2004-03-29 Therapeutic use of modulators of notch and/or kruppel-like factors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0307472.1A GB0307472D0 (en) 2003-04-01 2003-04-01 Medical treatment

Publications (1)

Publication Number Publication Date
GB0307472D0 true GB0307472D0 (en) 2003-05-07

Family

ID=9955935

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0307472.1A Ceased GB0307472D0 (en) 2003-04-01 2003-04-01 Medical treatment

Country Status (2)

Country Link
GB (1) GB0307472D0 (en)
WO (1) WO2004087195A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
WO2022253794A2 (en) * 2021-06-02 2022-12-08 Cellestia Biotech Ag Method for treating an autoimmune and inflammatory disease
CN116466095B (en) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 Polypeptide and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
JPH11508771A (en) * 1995-06-28 1999-08-03 インペリアル カンサー リサーチ テクノロジー，リミテッド Vertebrate Delta gene nucleotide and protein sequences and methods based thereon
CA2260365C (en) * 1996-07-16 2004-08-10 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation-suppressive polypeptide
US5928941A (en) * 1996-10-07 1999-07-27 President And Fellows Of Harvard College Repressor kruppel-like factor
RO120850B1 (en) * 1996-11-07 2006-08-30 Imperial College Of Science Technology & Medic Notch
EP1096946A2 (en) * 1998-07-13 2001-05-09 Yale University Delta cleavage products and methods based thereon
GB9824045D0 (en) * 1998-11-03 1998-12-30 European Molecular Biology Lab Embl Regulator protein
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
AU2001284790A1 (en) * 2000-08-09 2002-02-18 Mount Sinai School Of Medicine Kruppel-like factor 6 (klf6), a tumorsuppressor protein, and dia gnostics, therapeutics, and screening based on this protein
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
DE10125893A1 (en) * 2001-05-28 2002-12-12 Georg Nickenig Medicament used for inhibiting vascular smooth muscle cell growth, especially for combating cardiovascular disease, contains gut enriched Kruppel-like factor related nucleotide sequence or corresponding polypeptide
WO2002098918A2 (en) * 2001-06-05 2002-12-12 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Novel targets for a therapeutic intervention in ebv related diseases
US7214488B2 (en) * 2001-07-03 2007-05-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services Detection of MECT1-MAML2 fusion products
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
JP2004537314A (en) * 2001-07-25 2004-12-16 ロランティス リミテッド Methods for detecting Notch signaling modulators
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
GB0201674D0 (en) * 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
WO2003074007A2 (en) * 2002-03-01 2003-09-12 Rigel Pharmaceuticals, Inc. Modulators of leukocyte activation, compositions, and methods of use
JP2006506322A (en) * 2002-04-05 2006-02-23 ロランティス リミテッド Internal medicine

Also Published As

Publication number Publication date
WO2004087195A2 (en) 2004-10-14
WO2004087195A3 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
GB0316912D0 (en) Therapeutic treatment
GB0320806D0 (en) Therapeutic treatment
GB0201674D0 (en) Medical treatment
GB0218879D0 (en) Medical treatment
GB0307863D0 (en) Therapeutic treatment
GB0300428D0 (en) Medical treatment
GB0313772D0 (en) Therapeutic treatment
GB0307472D0 (en) Medical treatment
GB0327493D0 (en) Treatment medicament
GB0306165D0 (en) Medical treatment
GB0301527D0 (en) Medical treatment
GB0323130D0 (en) Medical treatment
GB0323233D0 (en) Medical treatment
GB0301529D0 (en) Medical treatment
GB0301524D0 (en) Medical treatment
GB0306582D0 (en) Medical treatment
GB0306583D0 (en) Medical treatment
GB0306621D0 (en) Medical treatment
GB0306622D0 (en) Medical treatment
GB0306624D0 (en) Medical treatment
GB0306626D0 (en) Medical treatment
GB0306640D0 (en) Medical treatment
GB0306644D0 (en) Medical treatment
GB0306650D0 (en) Medical treatment
GB0306651D0 (en) Medical treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)